|
US3274118A
(en)
|
1962-01-22 |
1966-09-20 |
Lithium Corp |
Preparation of stable non-pyrophoric organometallic compositions
|
|
US5721356A
(en)
|
1989-09-15 |
1998-02-24 |
Gensia, Inc. |
Orally active adenosine kinase inhibitors
|
|
US5962473A
(en)
|
1996-08-16 |
1999-10-05 |
Eli Lilly And Company |
Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
|
|
US6608053B2
(en)
|
2000-04-27 |
2003-08-19 |
Yamanouchi Pharmaceutical Co., Ltd. |
Fused heteroaryl derivatives
|
|
EP1343506A1
(de)
|
2000-12-19 |
2003-09-17 |
MERCK PATENT GmbH |
Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate
|
|
EP2168576A3
(en)
|
2001-09-14 |
2010-05-26 |
Shionogi & Co., Ltd. |
Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases
|
|
ES2285164T3
(es)
|
2002-09-04 |
2007-11-16 |
Schering Corporation |
Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
|
|
MY133311A
(en)
|
2002-09-19 |
2007-11-30 |
Schering Corp |
Novel imidazopyridines as cyclin dependent kinase inhibitors
|
|
JP4895806B2
(ja)
|
2003-04-09 |
2012-03-14 |
エクセリクシス， インク． |
Ｔｉｅ−２モジュレータと使用方法
|
|
AR047969A1
(es)
|
2004-02-25 |
2006-03-15 |
Schering Corp |
Pirazolotriazinas como inhibidores de quinasa
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
JP2008520749A
(ja)
|
2004-11-23 |
2008-06-19 |
レディ ユーエス セラピューティックス， インコーポレイテッド |
新規二環式ヘテロ環化合物、その調製のためのプロセス、およびその新規二環式ヘテロ環化合物を含む組成物
|
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
|
PL1879573T3
(pl)
|
2005-05-10 |
2013-05-31 |
Incyte Holdings Corp |
Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
US8450351B2
(en)
|
2005-12-20 |
2013-05-28 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
WO2008036642A2
(en)
|
2006-09-19 |
2008-03-27 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
|
WO2008058126A2
(en)
|
2006-11-06 |
2008-05-15 |
Supergen, Inc. |
Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
US10047066B2
(en)
|
2007-11-30 |
2018-08-14 |
Newlink Genetics Corporation |
IDO inhibitors
|
|
JP5643105B2
(ja)
|
2007-12-14 |
2014-12-17 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
新規イミダゾ［１，２−ａ］ピリジン及びイミダゾ［１，２−ｂ］ピリダジン誘導体
|
|
WO2009156652A1
(fr)
|
2008-05-29 |
2009-12-30 |
Saint-Gobain Centre De Recherches Et D'etudes Europeen |
Structure en nid d'abeille a base de titanate d'aluminium
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
PE20100362A1
(es)
|
2008-10-30 |
2010-05-27 |
Irm Llc |
Derivados de purina que expanden las celulas madre hematopoyeticas
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-ｇｉｔｒ 항체
|
|
EP2493862B1
(en)
|
2009-10-28 |
2016-10-05 |
Newlink Genetics Corporation |
Imidazole derivatives as ido inhibitors
|
|
JP5802676B2
(ja)
|
2009-12-04 |
2015-10-28 |
センワ バイオサイエンシズ インコーポレイテッド |
Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
|
|
ES2722300T3
(es)
|
2009-12-10 |
2019-08-09 |
Hoffmann La Roche |
Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
|
|
EP2542256B1
(en)
|
2010-03-04 |
2019-05-22 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
JP5989547B2
(ja)
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
US9169323B2
(en)
|
2010-03-05 |
2015-10-27 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R
|
|
HRP20190047T1
(hr)
|
2010-05-04 |
2019-02-22 |
Five Prime Therapeutics, Inc. |
Protutijela koja se vežu na csf1r
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
WO2012044562A2
(en)
|
2010-09-30 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine pde10 inhibitors
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
GB201103837D0
(en)
|
2011-03-07 |
2011-04-20 |
Oxagen Ltd |
Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
|
|
NO2694640T3
(https=)
|
2011-04-15 |
2018-03-17 |
|
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
AP2013007253A0
(en)
|
2011-04-21 |
2013-11-30 |
Origenis Gmbh |
Pyrazolo [4,3-D] pyrimidines useful as kinase inhibitors
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
EP2788476B1
(en)
|
2011-12-08 |
2019-05-22 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
|
|
RU2658603C2
(ru)
|
2011-12-15 |
2018-06-21 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против человеческого csf-1r и их применения
|
|
KR20140127855A
(ko)
|
2012-02-06 |
2014-11-04 |
제넨테크, 인크. |
Csf1r 억제제를 사용하는 조성물 및 방법
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
AR090650A1
(es)
|
2012-04-12 |
2014-11-26 |
Alcon Res Ltd |
Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
|
|
RU2670743C9
(ru)
|
2012-05-11 |
2018-12-19 |
Файв Прайм Терапьютикс, Инк. |
Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
WO2014060112A1
(en)
|
2012-10-19 |
2014-04-24 |
Origenis Gmbh |
Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
|
|
WO2014138485A1
(en)
|
2013-03-08 |
2014-09-12 |
Irm Llc |
Ex vivo production of platelets from hematopoietic stem cells and the product thereof
|
|
MX388871B
(es)
*
|
2014-06-27 |
2025-03-20 |
Nogra Pharma Ltd |
Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
|
|
CN108290855A
(zh)
|
2015-07-01 |
2018-07-17 |
西北大学 |
被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
|
|
US20180072741A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyrimidine compounds and uses thereof
|
|
TW201841916A
(zh)
|
2017-04-12 |
2018-12-01 |
美商麥珍塔治療學股份有限公司 |
芳香烴受體拮抗劑及其用途
|
|
MX2019012431A
(es)
|
2017-04-21 |
2020-08-03 |
Ikena Oncology Inc |
Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
|
|
EP3867253A4
(en)
|
2018-10-16 |
2022-05-18 |
Ikena Oncology, Inc. |
Indole ahr inhibitors and uses thereof
|
|
AU2020394424A1
(en)
|
2019-11-26 |
2022-06-16 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
|
EP4065090A1
(en)
|
2019-11-26 |
2022-10-05 |
Ikena Oncology, Inc. |
Ahr inhibitors and uses thereof
|
|
CA3167283A1
(en)
|
2020-01-10 |
2021-07-15 |
Ikena Oncology, Inc. |
Ahr inhibitors and uses thereof
|
|
MX2023004847A
(es)
|
2020-10-28 |
2023-07-11 |
Ikena Oncology Inc |
Combinación de un inhibidor del receptor de hidrocarburos de arilo (ahr) con un inhibidor de pdx o doxorrubicina.
|